Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 11;289(28):19351-63.
doi: 10.1074/jbc.M114.558882. Epub 2014 May 15.

Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor

Affiliations

Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor

Anthony Yiu-Ho Woo et al. J Biol Chem. .

Abstract

Interaction of a given G protein-coupled receptor to multiple different G proteins is a widespread phenomenon. For instance, β2-adrenoceptor (β2-AR) couples dually to Gs and Gi proteins. Previous studies have shown that cAMP-dependent protein kinase (PKA)-mediated phosphorylation of β2-AR causes a switch in receptor coupling from Gs to Gi. More recent studies have demonstrated that phosphorylation of β2-AR by G protein-coupled receptor kinases, particularly GRK2, markedly enhances the Gi coupling. We have previously shown that although most β2-AR agonists cause both Gs and Gi activation, (R,R')-fenoterol preferentially activates β2-AR-Gs signaling. However, the structural basis for this functional selectivity remains elusive. Here, using docking simulation and site-directed mutagenesis, we defined Tyr-308 as the key amino acid residue on β2-AR essential for Gs-biased signaling. Following stimulation with a β2-AR-Gs-biased agonist (R,R')-4'-aminofenoterol, the Gi disruptor pertussis toxin produced no effects on the receptor-mediated ERK phosphorylation in HEK293 cells nor on the contractile response in cardiomyocytes expressing the wild-type β2-AR. Interestingly, Y308F substitution on β2-AR enabled (R,R')-4'-aminofenoterol to activate Gi and to produce these responses in a pertussis toxin-sensitive manner without altering β2-AR phosphorylation by PKA or G protein-coupled receptor kinases. These results indicate that, in addition to the phosphorylation status, the intrinsic structural feature of β2-AR plays a crucial role in the receptor coupling selectivity to G proteins. We conclude that specific interactions between the ligand and the Tyr-308 residue of β2-AR stabilize receptor conformations favoring the receptor-Gs protein coupling and subsequently result in Gs-biased agonism.

Keywords: Adrenergic Receptor; Cardiomyocyte Contraction; Cardiovascular; Functional Selectivity; G Protein-coupled Receptor (GPCR); Molecular Docking; Molecular Pharmacology; Signal Transduction; Site-directed Mutagenesis.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Structures of Fen and its derivatives used in the study. The following terms are used: fenoterol (Fen), 4′-methoxyfenoterol (methoxyFen); 4′-aminofenoterol (aminoFen); phenylfenoterol (PhFen); 1-naphthylfenoterol (1-NapFen); ethylfenoterol (EtFen); 2-naphthylfenoterol (2-NapFen); and 4′-methoxy-1-naphthylfenoterol (MNFen).
FIGURE 2.
FIGURE 2.
Substitution on the aminoalkyl portion of (R,R′)-Fen determines the PTX sensitivity of the agonist-stimulated contractile response in rat cardiomyocytes. Concentration-response profiles of cardiomyocyte contractility in cells subjected to (R,R′)-PhFen (A), (R,R′)-aminoFen (B), (R,R′)-1-NapFen (C), and (R,R′)-MNFen (D) with (▴) and without (○) PTX treatment (0.75 μg/ml at 37 °C for >3 h). Contractile response to the agonist is expressed as a percentage of the basal contractility (mean ± S.E., n = 9–11 cells from 5 to 9 hearts for each data point).
FIGURE 3.
FIGURE 3.
(R,R′)-AminoFen exhibits β2-AR subtype selectivity in cardiomyocyte contractile response. Single ventricular myocytes from rats were set to pace under perfusion. The contraction amplitude of a cell in response to (R,R′)-aminoFen (0.1 μm) followed by ICI-118,551 (ICI, 0.1 μm) was monitored. Steady-state contractility was recorded. Contractile response is expressed as a percentage of the basal contractility. Data are means ± S.E., n = 4 cells from four hearts. ***, p < 0.001 (by paired t test).
FIGURE 4.
FIGURE 4.
Addition of forskolin reconstitutes functional coupling of β2-AR to Gi protein in cultured β2-AR knock-out mouse cardiomyocytes induced with human β2-AR. Cardiomyocytes from β2-AR knock-out mice were infected with adeno-GFP (white bar) or adeno-β2-AR (black bars) and cultured for 24 h in the presence or absence of forskolin (1 μm) and/or PTX (0.75 μg/ml) as indicated. Cells were transferred to a perfusion chamber, electrically paced, and subjected to stimulation with zinterol (0.2 μm, a concentration without an inotropic effect in freshly isolated cardiomyocytes from WT mice, see Fig. 1A in Ref. 26). Steady-state contractility was measured. Data (mean ± S.E., n = 10–15 cells from 5 to 9 hearts for each data point) are expressed as percentages of the basal contractility. *, p < 0.05. Zinterol (0.2 μm) did not increase contractility in cells infected with adeno-GFP demonstrating no β1-AR stimulatory effect at this concentration. In cells infected with adeno-β2-AR and cultured in the absence of forskolin, the inotropic response produced by zinterol stimulation was the result of a pure β2-AR-Gs-mediated effect because β2-AR and Gi proteins were functionally uncoupled. In cells infected with adeno-β2-AR in the presence of forskolin, the coupling of β2-AR to Gi protein was reestablished. Therefore, the cardiomyocytes were unresponsive to zinterol as if they were freshly isolated WT β2-AR+ cells when β2-AR-Gi coupling was intact. In cells infected with adeno-β2-AR in the presence of forskolin and PTX, the coupling of β2-AR to Gi protein still occurred, but Gi had lost its function and could no longer negatively regulate β2-AR-Gs activation by zinterol.
FIGURE 5.
FIGURE 5.
PTX increases the inotropic effect of (R,R′)-aminoFen in cardiomyocytes expressing β2-AR Y308F mutant but not in cardiomyocytes expressing WT human β2-AR. A, (R,R′)-aminoFen-stimulated contractile responses in β2-AR knock-out mouse cardiomyocyte adenoviral gene transfer GFP. Cardiomyocytes from β2-AR knock-out mice were infected with adeno-GFP and cultured for 24 h. Cells were paced under perfusion and subjected to (R,R′)-aminoFen (100, 500, or 1000 nm). Steady-state contractility before and after agonist stimulation was measured. B, (R,R′)-aminoFen-stimulated contractile responses in β2-AR knock-out mouse cardiomyocytes adenoviral gene transfer WT β2-AR in the presence or absence of PTX treatment. Cardiomyocytes from β2-AR knock-out mice were infected with adeno-β2-AR and cultured with or without PTX (0.75 μg/ml) for 24 h. Cells were paced under perfusion and subjected to (R,R′)-aminoFen (10, 100, or 500 nm). C, (R,R′)-aminoFen-stimulated contractile responses in β2-AR knock-out mouse cardiomyocyte adenoviral gene transfer β2-AR Y308F in the presence or absence of PTX treatment. Contractile responses are expressed as percentages of the basal contractility (mean ± S.E., n = 9–14 cells from 4 to 8 hearts for each data point). Concentration dependence of the (R,R′)-aminoFen-stimulated responses was verified (by two-way analysis of variance, p < 0.0001) for all datasets. *, p < 0.05; ***, p < 0.001 versus corresponding −PTX group.
FIGURE 6.
FIGURE 6.
Y308F substitution on β2-AR increases the PTX sensitivity of (R,R′)-aminoFen-induced ERK phosphorylation in HEK stable cell lines. Confluent cultures of HEK-β2-AR cells and HEK-β2-AR Y308F cells were deprived of serum overnight. Treatment with PTX (0.3 μg/ml, +) or vehicle (−) was implemented during serum starvation. Cells were then stimulated with ISO (1 μm) or (R,R′)-aminoFen (10−9 to 10−6 m) for 5 min at 37 °C as indicated. ERK phosphorylation was determined by immunoblotting. A, immunoblots of p-ERK and total ERK (as protein loading control) in response to agonist stimulation in HEK-β2-AR cells, and B, averaged data. C, immunoblots of p-ERK and total ERK in response to agonist stimulation in HEK-β2-AR Y308F cells, and D, averaged data. Data are presented as fold increase over −PTX control (means ± S.E. in 3–4 independent experiments). *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus vehicle controls; #, p < 0.05 versus −PTX group.
FIGURE 7.
FIGURE 7.
Y308F substitution on β2-AR increases the PTX sensitivity of (R,R′)-aminoFen-stimulated cAMP production in HEK stable cell lines. HEK-β2-AR cells and HEK-β2-AR Y308F cells were cultured in 12-well plates in parallel, and subsets of the cells were treated with PTX (0.3 μg/ml) or vehicle overnight. Agonist stimulation was allowed to proceed for 10 min at 25 °C in the presence of 3-isobutyl-1-methylxanthine (1 mm). Cellular cAMP contents were determined by enzyme immunoassay. HEK-β2-AR cells were subjected to (R,R′)-aminoFen (10−11 to 10−6 m) (A), and HEK-β2-AR Y308F cells were subjected to (R,R′)-aminoFen (B), with (▴) and without (○) PTX treatment. Data (means ± S.E. in three independent experiments performed in triplicate) are expressed as percentages of the Emax response of the β2-AR WT −PTX group. Curve-fitting analysis of the concentration-response curves were conducted using Prism. **, p < 0.01 versus −PTX group.
FIGURE 8.
FIGURE 8.
(R,R′)-AminoFen induces phosphorylation of β2-AR and β2-AR Y308F mutant at the GRK and the PKA sites in HEK stable cell lines. Confluent cultures of HEK-β2-AR cells and HEK-β2-AR Y308F cells were incubated in serum-free medium for 3 h and then stimulated with vehicle control (−), ISO (1 μm), or (R,R′)-aminoFen (R, 1 μm; R100 for WT, 0.2 μm; R100 for Y308F, 1 μm; R1000 for WT, 2 μm; R1000 for Y308F, 10 μm) for 5 min at 37 °C. Phosphorylated β2-AR was detected by phosphosite-specific antibodies against Ser(P)-262 for PKA sites and Ser(P)-355,356 for GRK sites. Total β2-AR was detected after stripping and reprobing the membrane with the β2-AR-CT antibody. A, immunoblots of Ser(P)-262-β2-AR and total β2-AR in response to agonist stimulation, and B, averaged data (normalized to total β2-AR). C, immunoblots of Ser(P)-355,356-β2-AR and total β2-AR in response to agonist stimulation, and D, averaged data. Data are expressed as fold increase over control (means ± S.E. in at least three independent experiments). *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus vehicle controls (two-way analysis of variance with post hoc t test). No significant differences were found for all within-group comparisons between WT and Y308F, p > 0.05.
FIGURE 9.
FIGURE 9.
Binding poses of (R,R′)-aminoFen and (R,R′)-MNFen docked to the β2-AR models. A, docking of (R,R′)-aminoFen to the carazolol-bound β2-AR model (PDB entry 2RH1), and B, to the β2-AR Y308F mutant. The 4′-amino group of (R,R′)-aminoFen forms a HB with the Tyr-308 residue of β2-AR (green arrow), and the interaction is lost in the β2-AR Y308F mutant. C, docking of (R,R′)-aminoFen to a BI-167107 and Gs protein-bound conformation of β2-AR (PDB entry 3SN6). The location of the docked molecule highly resembles the orientation of co-crystallized agonist, BI-167107, as both molecules share significant structural similarities. The agonists form a network of analogous HB interactions with the receptor residues Ser-203, Ser-207, Asn-312, and Asp-113. An additional interaction can be observed between the 4′-amino moiety of the ligand and Lys-305 residue. D, docking of (R,R′)-MNFen to a carazolol-bound conformation of β2-AR (PDB entry 2RH1). Aromatic residues in the ligand binding pocket able to form π-π interactions with the naphthyl moiety of the ligand are shown. Ligand molecule is rendered in atom-type color-coded stick mode, and five essential TM helices of target β2-AR model are shown and colored as follows: TM3, magenta; TM4, green; TM5, red; TM6, yellow; and TM7, blue.

Similar articles

Cited by

References

    1. Violin J. D., Lefkowitz R. J. (2007) β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28, 416–422 - PubMed
    1. Kenakin T. (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28, 407–415 - PubMed
    1. Mailman R. B. (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci. 28, 390–396 - PMC - PubMed
    1. Urban J. D., Clarke W. P., Zastrow M. V., Nichols D. E., Kobilka B., Weinstein H. (2007) Functional selectivity and classical concepts of quantitative pharmacology. Pharmacology 320, 1–13 - PubMed
    1. Neubig R. R. (2007) Missing links: mechanisms of protean agonism. Mol. Pharmacol. 71, 1200–1202 - PubMed

Publication types

MeSH terms

Substances